Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer

BACKGROUND: Intermediate endpoints, such as disease-free survival (DFS), have shown good correlation with overall survival (OS) in early-stage non–small cell lung cancer (NSCLC) clinical trials. However, real-world data are limited, and no previous real-world study has quantified the clinical and ec...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Howard, Hu, Xiaohan, Zhang, Su, Song, Yan, Chirovsky, Diana, Gao, Chi, Lerner, Ari, Jiang, Anya, Signorovitch, James, Samkari, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387987/
https://www.ncbi.nlm.nih.gov/pubmed/37404067
http://dx.doi.org/10.18553/jmcp.2023.29.7.749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387987/
https://www.ncbi.nlm.nih.gov/pubmed/37404067
http://dx.doi.org/10.18553/jmcp.2023.29.7.749

Ejemplares similares